# Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

> **NCT05851378** · EARLY_PHASE1 · RECRUITING · sponsor: **Robert Bok, MD, PhD** · enrollment: 40 (estimated)

## Conditions studied

- Adult Gliomas, Mixed

## Interventions

- **DRUG:** Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
- **PROCEDURE:** Magnetic Resonance Image (MRI)

## Key facts

- **NCT ID:** NCT05851378
- **Lead sponsor:** Robert Bok, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-11
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05851378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05851378, "Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05851378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*